Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Company) and Adaptimmune Therapeutics plc (Adaptimmune) entered
into a Co-Development and Co-Commercialisation Agreement (the
Agreement) in order to facilitate a staged collaboration to
evaluate, develop and commercialize next generation T cell
therapies.
GoTCR technology (inducible MyD88/CD40 co-stimulation, or iMC)
with Adaptimmunes affinity-optimized SPEAR>T cells for the
potential to create enhanced TCR product candidates. Depending on
results of the preclinical proof-of-concept phase, the parties
expect to progress to a two-target co-development and
co-commercialization phase. To the extent necessary, and in
furtherance of the parties proof-of-concept and co-development
efforts, the parties granted each other a royalty-free,
non-transferable, non-exclusive license covering their respective
technologies for purposes of facilitating such proof-of-concept
and co-development efforts. In addition, as to covered therapies
developed under the agreement, the parties granted each other a
reciprocal exclusive license for the commercialization of such
therapies.
the parties agreed to negotiate in good faith the commercially
reasonable terms of a co-commercialization agreement. The parties
also agreed that any such agreement shall provide for, among
other things, equal sharing of the costs of any such joint
commercialization and the calculation of profit shares as set
forth in the Agreement.
parties cease commercialization of the T cell therapies covered
by the Agreement, unless earlier terminated by either party for
material breach, non-performance or cessation of development,
bankruptcy/insolvency, or failure to progress to co-development
phase.
purport to be complete and is qualified in its entirety by
reference to the complete text of the Agreement, including the
exhibits thereto, a copy of which will be filed as an exhibit to
the Companys Annual Report on Form 10-K for the fiscal year ended
December 31, 2016.
announcing the Agreement. A copy of this press release is
attached hereto as Exhibit 99.1.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated December 19, 2016.
|
About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Recent Trading Information
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed its last trading session down -0.68 at 14.73 with 276,090 shares trading hands.
